Literature DB >> 26835734

Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates.

Mohadeseh Haji Abdolvahab1, Ahmad Fazeli2, Andhyk Halim1, Ahmad S Sediq3, Mohammad Reza Fazeli4, Huub Schellekens1.   

Abstract

Determining to what extent biophysical characteristics of aggregates affect immunogenicity of therapeutic interferon beta-1b. Three recombinant human interferon beta-1b (rhIFNβ-1b) samples with different levels of aggregates generated by copper oxidation, thermal stress, or left untreated, as well as Avonex(®) drug substance and Betaferon(®) drug product, were injected intraperitoneally in nontransgenic and interferon beta transgenic FVB/N mice 5 times per week for 3 weeks. Antibodies against interferon beta were measured using enzyme-linked immunosorbent assay. UV and fluorescence spectroscopy, dynamic light scattering, size exclusion chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), fluid imaging microscopy, and resonant mass measurement, as well as sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting, were used to characterize and quantitate aggregates in the 3 rhIFNβ preparations, to correlate biophysical characteristics with immunogenicity. In immune-tolerant interferon beta transgenic FVB/N mice, Betaferon drug product showed the highest immunogenicity, while Avonex drug substance showed the lowest level of immunogenicity. Of the 3 forms of rhIFNβ-1b, copper-oxidized rhIFNβ-1b showed lower immunogenicity than thermally stressed rhIFNβ-1b, despite containing larger aggregates. Both copper-oxidized rhIFNβ-1b and thermally stressed rhIFNβ-1b exhibited changes in protein structure as shown using fluorescence spectroscopy and RP-HPLC. Nontransgenic, nonimmune-tolerant FVB/N mice generated high antibody titers against all interferon beta samples tested. The level of immunogenicity and the breaking of tolerance in FVB/N transgenic mice are not only related to the level of aggregation but also depend on the size and structure of the aggregates.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26835734     DOI: 10.1089/jir.2015.0108

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Effect of Chemical Oxidation on the Higher Order Structure, Stability, Aggregation, and Biological Function of Interferon Alpha-2a: Role of Local Structural Changes Detected by 2D NMR.

Authors:  Dinen D Shah; Surinder M Singh; Krishna M G Mallela
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

2.  Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta.

Authors:  Lydia Asrat Haile; Swamy Kumar Polumuri; Roshni Rao; Logan Kelley-Baker; Dimitri Kryndushkin; Rajesh Rajaiah; Tomer Israely; V Ashutosh Rao; Daniela Verthelyi
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 3.  Why the Immune System Should Be Concerned by Nanomaterials?

Authors:  Marc J Pallardy; Isabelle Turbica; Armelle Biola-Vidamment
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

Review 4.  Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates.

Authors:  Myriam Nabhan; Marc Pallardy; Isabelle Turbica
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 5.  Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Authors:  Alison Smith; Hugh Manoli; Stacey Jaw; Kimberley Frutoz; Alan L Epstein; Leslie A Khawli; Frank-Peter Theil
Journal:  J Immunol Res       Date:  2016-08-08       Impact factor: 4.818

6.  Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response.

Authors:  Kirsty D Ratanji; Rebecca J Dearman; Ian Kimber; Robin Thorpe; Meenu Wadhwa; Jeremy P Derrick
Journal:  Toxicol Sci       Date:  2016-06-30       Impact factor: 4.849

7.  Treatment with recombinant human bone morphogenetic protein 7 leads to a transient induction of neutralizing autoantibodies in a subset of patients.

Authors:  Andrea Schuette; Arash Moghaddam; Petra Seemann; Georg N Duda; Gerhard Schmidmaier; Lutz Schomburg
Journal:  BBA Clin       Date:  2016-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.